TABLE 2.
Review of reported cases of Citalopram/Escitalopram-induced SIADH: comparison of genotype availability and cardiac monitoring.
| Author (Year) | Patient (Age/Sex) | Drug and Doseage |
Lowest Na+ (mmol/L) | CYP2C19 Genotype |
Cardiac monitoring (HR/QTc) | SIADH markers (U-Na/S-Uric Acid) |
|---|---|---|---|---|---|---|
| Barclay and Lee (2002) a | 87/M | Citalopram 20 mg | 122 | NR | HR 62 bpm (normal) | U-Na: 67 S-UA: Low |
| Tsai et al. (2012) | 73/F | Escitalopram 10 mg | 122 | NR | NR | U-Na: 64 S-UA: NR |
| Kacperczyk et al. (2021) | 85/F | Escitalopram 5 mg | 123 | NR | NR | Diagnosis by exclusion |
| 84/F | Escitalopram 5 mg | 124 | NR | NR | Diagnosis by exclusion | |
| Prakash et al. (2021) | 82/F | Escitalopram 5 mg | 115 | NR | Tachycardia (120 bpm) | U-Na: High
b
S-UA: NR |
| Present case | 51/F | Escitalopram 10 mg Quetiapine 50 mg |
114.7 | *1*/2 (IM) | Prolonged (570 ms) Bradycardia |
U-Na: 220 S-UA: 76 |
Abbreviations: NR: not reported; IM: intermediate metabolizer; U-Na: Urine Sodium (mmol/L); S-UA: Serum Uric Acid (μmol/L); HR: heart rate.
a
Classic report reviewing earlier cases (e.g., Bouman 1998; Odeh 2001).
b
Qualitative description in text; exact value not provided.